Page last updated: 2024-11-05

trazodone and MPTP Neurotoxicity Syndrome

trazodone has been researched along with MPTP Neurotoxicity Syndrome in 1 studies

Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.

Research Excerpts

ExcerptRelevanceReference
"Trazodone is a clinically available anti-depressant that exhibits affinity for serotonin 1A and 2A receptors, as well as for alpha-adrenoceptors, suggesting that it may be useful to treat L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis that are encountered in advanced Parkinson's disease (PD)."1.48Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease. ( Gourdon, JC; Hamadjida, A; Huot, P; Nuara, SG, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hamadjida, A1
Nuara, SG1
Gourdon, JC1
Huot, P1

Other Studies

1 other study available for trazodone and MPTP Neurotoxicity Syndrome

ArticleYear
Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:9

    Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Callithrix; Disorders of Exce

2018